MUMBAI, India, July 7 -- Intellectual Property India has published a patent application (202617069226 A) filed by Fondazione Per Listituto Oncologico Di; and Fondazione Per L'Istituto Di Ricerca In on June 02, 2026, for An Antibody-Based Strategy Targeting Activated Oncogenic Erg In Prostate Cancer.
Inventors include Catapano, Carlo Number; Carbone, Giuseppina; Cavalli, Andrea; Guerra, Concetta; and Sgrignani, Jacopo.
The application for the patent was published on July 03, 2026, under issue no. 27/2026.
Abstract: The present invention relates to antibodies or antigen-binding portion thereof that are capable of specifically binding to a methylated ETS transcription factor ERG, for use in the prophylactic and/or therapeutic treatment of a prostate cancer in a subject in need thereof. The invention relates also to the use of such antibodies or an antigen-binding portion thereof in the diagnosis or prognosis of prostate cancer.
Disclaimer: Curated by HT Syndication.
